Six-Year Follow Up Of Phase III Sprycel Trial Demonstrates 71 Percent Overall Survival
FDA Approves Afinitor-Aromasin Regimen For Advanced HER2-Negative Breast Cancer
Phase III Study Evaluating Halaven Fails To Meet Primary Endpoints
Upper Endoscopy Most Effective When Performed in 3-Year Intervals
Women Who Concieve Using Fertility Drugs Have a Higher Risk Of Breast Cancer Than Non-Users
Variation in Breast Density May Be Strong Risk Factor
Study: Molecular Breast Imaging Can Be As Effective as MRI
Mammography Had Limited Impact Among Swedish Women Age 40-69
High Vitamin E Consumption Can Lower Liver Cancer Risks
Gene Expression Test Accurately Classifies “Inconclusive” Samples
CAP, ASCCP Recommendations Standardize Lesion Terminology
NCI-Approved CTEP Trials For The Month of July
Trending Stories
- How George Tidmarsh crossed the FDA-industry Rubicon
- CDER Director Tidmarsh quits amid inspector general probe of his “personal conduct”
Cancer advocates express concern about comments that signal trouble for accelerated approval - Tidmarsh is out, Pazdur is in: FDA’s CDER under new leadership
- City of Hope’s leadership in lung cancer: Precision, innovation, and a vision for cure
- Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA
- Mary Pazdur, 63, Dies of Cancer; What Her Husband Has Learned
